Instant NanoBiosensors

Executive Summary

Instant NanoBiosensors (INB) is a Taiwan-based med-tech company developing high-throughput optical biosensing and automated nucleic acid workflows for precision diagnostics. Its proprietary FOPPR™ (Fiber-Optic Particle Plasmon Resonance) technology enables rapid, label-free detection of protein and nucleic-acid biomarkers, while the iNA™ suite automates NGS library preparation and targeted panel testing. INB focuses on early disease detection in neurology, oncology, and infectious disease, positioning itself as a platform player in the diagnostics market. Founded in 2020 and currently employing 50-200 staff, the company operates in the private stage without disclosed funding or revenue. With its novel biosensing platform and automated workflows, INB aims to address unmet needs in rapid, cost-effective diagnostics, particularly in point-of-care and decentralized testing settings. The company's technologies have the potential to improve turnaround times and accessibility for biomarker detection, though commercial validation and regulatory clearances remain key milestones.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for FOPPR-based diagnostic test for infectious disease60% success
• 2026Commercial launch of iNA NGS library preparation system65% success
• 2026Strategic partnership with a global diagnostics company for distribution55% success